Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.19 HKD | +0.63% | -2.74% | -24.76% |
Apr. 03 | Alibaba Health Refutes Rumors of Purchase of Telemedicine Platform HaoDF | MT |
Mar. 28 | Alibaba Health Information Technology Limited and Alibaba.com Enter Shared Services Agreement | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 59.88 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.76% | 6.52B | B | ||
-34.16% | 14.83B | B- | ||
-22.12% | 12.04B | B | ||
+14.96% | 6.44B | C | ||
-9.27% | 6.15B | C+ | ||
-2.92% | 4.63B | D- | ||
+60.00% | 4.62B | C | ||
-8.10% | 3.93B | B | ||
-11.16% | 3.49B | C- | ||
-6.69% | 3.05B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 241 Stock
- Ratings Alibaba Health Information Technology Limited